- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07622212
Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis
26 maj 2026 uppdaterad av: RenJi Hospital
Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis (The COMET Study)
A head-to-head comparison of two different types of percutaneous mechanical thrombectomy (PMT) - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - in patients with acute iliofemoral deep vein thrombosis (DVT) was conducted to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.
Studieöversikt
Status
Rekrytering
Betingelser
Detaljerad beskrivning
Acute deep venous thrombosis (DVT) is associated with development of post-thrombotic syndrome (PTS).
Early removal of iliofemoral thrombosis by percutaneous mechanical thrombectomy (PMT) may reduce the incidence of PTS.
There is currently a lack of research on which device is optimal for thrombus removal.
The aim of this study is to conduct a multicenter, observational, prospective cohort study in patients with acute iliofemoral deep vein thrombosis (DVT), performing a head-to-head comparison of two different types of mechanical thrombectomy devices - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.
Studietyp
Observationell
Inskrivning (Beräknad)
180
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Qihong Ni
- Telefonnummer: +8615801900772
- E-post: niqihong1989@163.com
Studieorter
-
-
-
Shanghai, Kina
- Rekrytering
- Renji Hospital
-
Kontakt:
- Qihong Ni
- Telefonnummer: +8615801900772
- E-post: niqihong1989@163.com
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Testmetod
Icke-sannolikhetsprov
Studera befolkning
180
Beskrivning
Inclusion Criteria:
- Aged between 18 and 85 years;
- Diagnosed with acute iliofemoral venous thrombosis, with thrombosis involving at least the iliac vein and common femoral vein;
- Time from symptom onset to endovascular treatment ≤ 14 days;
- Patients undergo endovascular treatment with percutaneous mechanical thrombectomy;
- Patients sign the informed consent form.
Exclusion Criteria:
- Presence of PTS in the limb to be treated in this procedure, or a history of symptomatic DVT in the same limb within the past 2 years;
- Concurrent symptomatic acute DVT involving the iliac vein and/or common femoral vein in the contralateral limb;
- Known allergy to heparin, low molecular weight heparin, contrast agents, etc.
- Concomitant severe pulmonary embolism with hemodynamic changes, such as hypoxia, hypotension, etc.
- Inability to tolerate endovascular treatment due to conditions such as acute systemic illness, severe dyspnea, etc.
- Concomitant severe renal insufficiency with creatinine clearance < 30 ml/min;
- Concomitant active bleeding, severe hepatic insufficiency, bleeding tendency, etc.
- Concomitant severe anemia (hemoglobin < 8.0 mg/dL) or platelet count < 80,000/mL;
- History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;
- Pregnant women;
- Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency, etc.) with an expected life expectancy < 24 months
- Participation in any drug or medical device clinical trial that may interfere with this study within the past 1 month;
- Patients unwilling to participate in this trial.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
ClotTriever System group
Patients receive percutaneous mechanical thrombectomy by ClotTriever System
|
The procedure is performed via the ipsilateral popliteal vein access or the ipsilateral femoral vein access.
After puncture under fluoroscopic or ultrasound guidance, a vascular sheath is inserted, systemic heparinization is administered, and a guidewire is advanced antegradely into the inferior vena cava with the assistance of a catheter to establish the access.
Once the access is established, treatment is carried out using stent retriever devices.
Available stent retriever devices include currently marketed options such as ClotTriever (INARI MEDICAL, USA).
After thrombectomy, the thrombus removal efficacy is assessed by venography.
|
|
Aspiration thrombectomy group
Patients receive percutaneous mechanical thrombectomy by aspiration or rheolytic thrombectomy
|
The procedure is performed via the ipsilateral calf deep vein access, the ipsilateral popliteal vein access, or the ipsilateral femoral vein access.
After puncture under fluoroscopic or ultrasound guidance, a vascular sheath is inserted, systemic heparinization is administered, and a guidewire is advanced antegradely into the inferior vena cava with the assistance of a catheter to establish the access.
Once the access is established, treatment is carried out using mechanical aspiration thrombectomy devices.
Available aspiration thrombectomy devices include currently marketed options such as the AngioJet thrombectomy catheter (Boston Scientific, USA) and the Acostream thrombectomy catheter (Acotec, China).
After thrombectomy, the thrombus removal efficacy is assessed by venography.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of PTS
Tidsram: At 24 months
|
Assessed by the Villalta score
|
At 24 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of moderate-to-severe PTS
Tidsram: at 6, 12, and 24 months
|
Assessed by the Villalta score
|
at 6, 12, and 24 months
|
|
Clinical classification of Clinical-Etiology-Anatomy-Pathophysiology (CEAP)
Tidsram: at 6, 12, and 24 months
|
Based on clinical symptoms
|
at 6, 12, and 24 months
|
|
Patency rate of the ipsilateral iliofemoral vein
Tidsram: at 12 months and 24 months
|
Assessed by color Doppler ultrasound
|
at 12 months and 24 months
|
|
Incidence of PTS
Tidsram: Assessed by the Villalta score
|
at 6 and 12 months
|
Assessed by the Villalta score
|
|
Recurrence rate of symptomatic Deep Vein Thrombosis (DVT)
Tidsram: at 24 months
|
Assessed by symptoms combined with ultrasound examination in the ipsilateral limb
|
at 24 months
|
|
Rate of re-intervention
Tidsram: at 24 months
|
Assessed by documentation of clinical reintervention
|
at 24 months
|
|
Quality of life score
Tidsram: at 6, 12, and 24 months
|
Assessed by Venous Insufficiency Epidemiological and Economic Study Quality of Life questionnaire (VEINES-QOL)
|
at 6, 12, and 24 months
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of major bleeding
Tidsram: at 24 months
|
Defined by International Society on Thrombosis and Haemostasis (ISTH) criteria
|
at 24 months
|
|
Incidence of symptomatic Pulmonary Embolism (PE)
Tidsram: at 24 months
|
Assessed by symptoms combined with contrast-enhanced computed tomography examination
|
at 24 months
|
|
Incidence of symptomatic Venous Thromboembolism (VTE)
Tidsram: at 24 months
|
Assessed by symptoms combined with ultrasound and contrast-enhanced computed tomography examination
|
at 24 months
|
|
All-cause mortality
Tidsram: at 24 months
|
All-cause death
|
at 24 months
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
1 januari 2024
Primärt slutförande (Beräknad)
31 december 2027
Avslutad studie (Beräknad)
31 december 2028
Studieregistreringsdatum
Först inskickad
26 maj 2026
Först inskickad som uppfyllde QC-kriterierna
26 maj 2026
Första postat (Faktisk)
3 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
3 juni 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
26 maj 2026
Senast verifierad
1 maj 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- The COMET Study
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .